Clinical Trial Update: HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing patritumab deruxtecan to platinum-based chemotherapy in EGFR-mutant non-small cell lung cancer after EGFR TKI failure; the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Nonsquamous Non-small Cell Lung Cancer, EGFR L858R | Phase 3 | Status: ACTIVE_NOT_RECRUITING